TN-401 treatment of Pkp2-cKO mice showed dose-dependent efficacy in preventing decline of LV ejection fraction, reducing RV dilation as estimated by RV area normalized to body weight, and a trending reduction in arrhythmias (Fig. 5b). This evidence concerns the gene PKP2 and cardiac arrhythmia.